Next Article in Journal / Special Issue
Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic
Previous Article in Journal
From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Previous Article in Special Issue
Safety Monitoring in Clinical Trials
Pharmaceutics 2013, 5(1), 168-178; doi:10.3390/pharmaceutics5010168
Commentary

Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities

Received: 31 December 2012; in revised form: 16 February 2013 / Accepted: 18 February 2013 / Published: 12 March 2013
(This article belongs to the Special Issue Drug Safety and Pharmacovigilance)
View Full-Text   |   Download PDF [165 KB, uploaded 12 March 2013]
Abstract: Since the late 1990s, there have been tremendous strides made in improving the capacity for carrying out routine active surveillance of new vaccines in the United States. These strides have led to new surveillance systems that are now in place. Some of the critical elements that are part of successful vaccine or drug safety surveillance systems include their use of (i) longitudinal data from a discrete enumerated population base, (ii) frequent, routine transfers of small amounts of data that are easy to collect and collate, (iii) avoidance of mission creep, (iv) statistical capabilities, (v) creation of an “industrialized process” approach and (vi) political safe harbor.
Keywords: vaccine safety, drug safety, surveillance vaccine safety, drug safety, surveillance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Davis, R.L. Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities. Pharmaceutics 2013, 5, 168-178.

AMA Style

Davis RL. Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities. Pharmaceutics. 2013; 5(1):168-178.

Chicago/Turabian Style

Davis, Robert L. 2013. "Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink’s Rapid Cycle Analysis Capabilities." Pharmaceutics 5, no. 1: 168-178.


Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert